Results 161 to 170 of about 128,640 (296)

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

Obesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

Administrative costs of prior authorizations for glucagon-like peptide-1 agonists. [PDF]

J Manag Care Spec Pharm
Pham D, Duby JJ, Setoudeh S, Knox S, Leahy K, Cruz D, Cutler T.   +6 more
europepmc   +1 more source

Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models

Obesity, EarlyView.
ABSTRACT Objective/Methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP‐1 receptor agonist retatrutide in diet‐induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
François Briand, Camille Le Cudennec, Estelle Grasset, Natalia Breyner, Claire Bigot, Pierre Dillard, Thierry Sulpice   +6 more
wiley   +1 more source

Signaling architecture of the glucagon-like peptide-1 receptor. [PDF]

J Clin Invest
Austin G, Tomas A.
europepmc   +1 more source

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

Obesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman, Young‐Rock Hong, Jamy Ard, Rebecca Jones, Adam Medcalf, Gary D. Foster, Jamil Alkhaddo, Michelle Cardel   +7 more
wiley   +1 more source

Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim, Pooja Gokhale, Akwasi Akosah, Lorenzo Villa‐Zapata   +3 more
wiley   +1 more source

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli

Diabetes, Metabolic Syndrome and Obesity
Carol Cheney,1 Krystal Hunter,1 Marlena Klein2 1Cooper Medical School of Rowan University, Camden, NJ, USA; 2Internal Medicine Department, Cooper University Hospital, Camden, NJ, USACorrespondence: Carol Cheney, Cooper Medical School of Rowan University,
Cheney C, Hunter K, Klein M
doaj  

Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]

BMJ Med
Batty JA, Del Toro T, Hall M.
europepmc   +1 more source